AstraZeneca just beat earnings on strong cancer drug sales, and KLA Corporation posted excellent results driven by demand for its specialized chipmaking equipment. Yet both stocks are being completely ignored because the entire market's attention is fixat

Verdict: genuine quality, premature trigger — wait for the crossover

The thesis that AstraZeneca and KLA Corporation are fundamentally strong companies being ignored during an AI-driven market panic is supported by genuine margin and cash-flow dominance — AZN's 82.0% gross margin and 94th-percentile operating margin, KLAC's 86.6% return on equity and 23.9% revenue growth — yet the setup is not actionable today because the EMA crossover entry gate has not triggered on either stock, with AZN roughly $4.0 away and KLAC $8.3 away on daily bars. The backtest is encouraging on returns (129% over 60 months, 25 trades) but discouraging on precision: a 48% win rate means more than half of trades lost, the 14.4% max drawdown on a 2.3% stop-loss strategy implies clustered losers, and exit fills were approximate rather than intrabar-verified. No robust parameter setup was established. XLV is closest to triggering but its RSI at 68.2 has already breached the 65 ceiling, removing it from the entry zone for now. The basket's near-zero pair correlations (diversification ratio of 1.60) are appealing but untested outside the observation window. **Conviction breakdown:** Thesis support is solid given the earnings beats and cooling oil narrative, but the rotation mechanism is an assumption rather than observable data. Trade readiness is low because neither AZN nor KLAC has triggered, and XLV has invalidated its RSI band. Risk quality is moderate — the 2:1 reward-to-risk is clean on paper, but the 48% win rate and clustered drawdowns temper it. Backtest evidence is mixed: strong headline returns but sub-50% win rate and approximate exit fills. Fundamentals are genuinely strong for both companies, though AZN's revenue growth sits in only the 37th percentile and KLAC carries cyclical leverage risk.

Trade now

All three tickers have cleared the RSI (14) band (above 35, below 65) as their first entry condition, but the momentum crossover is the remaining gatekeeper. For AZN, the 9-day EMA sits at $170 while the 21-day EMA is at $174 — the nine needs to cross above the twenty-one, and it is roughly $4 away. KLAC is further off: its 9-day EMA at $207 trails the 21-day at $215, a gap of about $8. XLV is the closest to triggering, with the 9-day EMA at $161 already above the 21-day at $160 by roughly $1, though RSI at 68 is bumping against the 65 ceiling on the upper bound and is only 3 points from invalidating that band. The VWAP condition (close above VWAP) cannot be assessed live because the VWAP reading is null across all three tickers today, so treat that as an unverified fourth gate. The backtested setup on AZN produced a 129% return over 60 months across 25 trades with a 48% win rate and a 14.4% max drawdown. Exits are defined by a 2.3% stop loss and a 4.7% take profit, yielding an effective reward-to-risk ratio of roughly 2:1. No robust parameter setup was established beyond the published rules. Position sizing caps at 25% of portfolio per position using a fixed-risk method keyed to a 78.6% Fibonacci retracement stop. "Wait" means concretely: set price or EMA alerts on the 9/21 crossover for AZN (trigger near $174) and KLAC (trigger near $215), and monitor XLV closely since its crossover is already live but RSI is pressing the upper bound. If XLV's RSI breaches 65, the RSI-band condition flips from met to invalidated and that ticker drops out of the entry zone until RSI cools back below 65. For AZN and KLAC, the EMA crossover has not occurred — no action until the nine crosses above the twenty-one on a daily close.

Fundamentals and backtest results both point to catch-up potential

The thesis rests on a simple but powerful premise: two companies with genuinely strong fundamentals are being overlooked because the market is fixated elsewhere. The numbers back this up. Per the Yahoo Finance piece on Q2 2026 earnings, AstraZeneca beat on cancer drug sales, and the fundamentals show why that strength is structural rather than cyclical. The company posts an 82.0% gross margin (78th percentile among Health Care peers) and a 23.4% operating margin that lands in the 94th percentile — elite territory. Revenue grew 8.6% year-over-year to $58.7B, and free cash flow hit $11.8B, placing AstraZeneca…

Scores

• Conviction score breakdown: 52
• Thesis support: 63
• Trade readiness: 25
• Risk quality: 48
• Backtest evidence: 52
• Fundamentals trend: 72

Watch items

• AZN — EMA (9) vs EMA (21) crossover
• KLAC — EMA (9) vs EMA (21) crossover
• XLV — RSI (14)
• AZN — RSI (14)
• KLAC — RSI (14)
• AZN — RSI (14) above 35
• AZN — RSI (14) below 65
• AZN — EMA (9) crossed above EMA (21)